$29.11
3.64% yesterday
Nasdaq, Nov 15, 10:02 pm CET
ISIN
US40131M1099
Symbol
GH

Guardant Health, Inc. Stock price

$29.11
+7.55 35.02% 1M
+3.36 13.05% 6M
+2.06 7.62% YTD
+6.29 27.56% 1Y
-74.54 71.92% 3Y
-50.90 63.62% 5Y
-3.09 9.60% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-1.10 3.64%
ISIN
US40131M1099
Symbol
GH
Sector

Key metrics

Market capitalization $3.60b
Enterprise Value $3.94b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.69
P/S ratio (TTM) P/S ratio 5.20
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 29.20%
Revenue (TTM) Revenue $692.26m
EBIT (operating result TTM) EBIT $-514.81m
Free Cash Flow (TTM) Free Cash Flow $-274.36m
Cash position $999.07m
EPS (TTM) EPS $-4.24
P/E forward negative
P/S forward 5.16
EV/Sales forward 5.63
Short interest 8.68%
Show more

Is Guardant Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Guardant Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Guardant Health, Inc. forecast:

22x Buy
92%
1x Hold
4%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Guardant Health, Inc. forecast:

Buy
92%
Hold
4%
Sell
4%

Financial data from Guardant Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
692 692
29% 29%
100%
- Direct Costs 275 275
30% 30%
40%
417 417
29% 29%
60%
- Selling and Administrative Expenses 546 546
33% 33%
79%
- Research and Development Expense 343 343
10% 10%
50%
-472 -472
1% 1%
-68%
- Depreciation and Amortization 43 43
2% 2%
6%
EBIT (Operating Income) EBIT -515 -515
1% 1%
-74%
Net Profit -512 -512
19% 19%
-74%

In millions USD.

Don't miss a Thing! We will send you all news about Guardant Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Guardant Health, Inc. Stock News

Neutral
Business Wire
2 days ago
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option awards to purc...
Positive
The Motley Fool
3 days ago
The rock star money manager is starting to roll with the rallying market.
Positive
Investors Business Daily
8 days ago
Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield. The post Guardant Health Rockets 25% On An 'Impressive' Beat Following Exact Sciences' Flop appeared first on Investor's Business Daily.
More Guardant Health, Inc. News

Company Profile

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Redwood City, CA.

Head office United States
CEO Helmy Eltoukhy
Employees 1,779
Founded 2012
Website www.guardanthealth.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today